Profound Medical
RELATED CONTENT
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Tulsa-Pro for ablation of prostate tissue.
August 16, 2019 
August 7, 2017 — Profound Medical Corp. recently announced that all closing conditions have been satisfied and it has ...
August 07, 2017 Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been successfully conducted at the ALTA Klinik in Bielefeld, Germany under the supervision of Agron Lumiani, M.D.
April 04, 2017 Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital (“Tyks”). The deal was completed in collaboration with Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.
March 22, 2017 
Philips and Profound Medical Corp., a Toronto-based medical device company, announced a joint development agreement to support Profound Medical's proprietary TULSA (Transurethral Ultrasound Ablation) technology on Philips' Ingenia and Achieva 3T magnetic resonance imaging (MRI) systems. The technology is designed to treat patients with prostate cancer
August 07, 2015